BioCryst to Present at Jefferies Virtual Healthcare Conference

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in the Jefferies Virtual Healthcare Conference on June 4, 2020, at 10:30 a.m. ET. The event aims to showcase the company's innovations in treating rare diseases through novel, oral, small-molecule medicines. Noteworthy development programs include berotralstat for hereditary angioedema and BCX9930, an oral Factor D inhibitor. A live audio webcast of the presentation will be available on BioCryst's website for investors.

RESEARCH TRIANGLE PARK, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10:30 a.m. ET.

Links to a live audio webcast and replay of this presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including berotralstat (BCX7353), an oral treatment for hereditary angioedema, BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB^® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

FAQ

When is BioCryst Pharmaceuticals presenting at the Jefferies Virtual Healthcare Conference?

BioCryst Pharmaceuticals will present at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 10:30 a.m. ET.

What is the stock symbol for BioCryst Pharmaceuticals?

The stock symbol for BioCryst Pharmaceuticals is BCRX.

Where can I access the presentation by BioCryst Pharmaceuticals?

The presentation by BioCryst Pharmaceuticals can be accessed via a live audio webcast on their website.

What are some key products in BioCryst Pharmaceuticals' development pipeline?

Key products include berotralstat for hereditary angioedema, BCX9930 for complement-mediated diseases, and galidesivir for COVID-19 and other viral diseases.